ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP78-22 Laboratory Reimbursement Policy Change will not be Implemented
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 28, 2022
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1251 - 1260 လၢ 4030 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP72-22 Executive Physical information added to Provider Policy and Procedure Manual
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 14, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP75-22 MHCP Pharmacy Benefit Exclusion for Alymsys® Byooviz™ and Igalmi™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 14, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP74-22 Commercial Pharmacy Benefit Exclusion for Byooviz™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 14, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP73-22 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective November 1, 2022
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 14, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2022 September Bulletins
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 01, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Medical and Behavioral Health Policy Activity Effective October 31, 2022
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P55-22 eviCore Healthcare Specialty Utilization Management (UM) Program: Radiation Oncology Clinical Guideline Updates
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 01, 2022